Drugs / BMF-650
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07223216 | Oct 2025 → May 2026 overdue | obesity disorder | Biomea Fusion Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Biomea Fusion Inc. | Results Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025 biomeafusion.com ↗
The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys |
| 2025-09-16 | Biomea Fusion Inc. | Regulatory Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update biomeafusion.com ↗
U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug Application (IND) for BMF-650, Biomea’s next-generation investigational oral glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), was recently received. |
| 2025-06-18 | Biomea Fusion Inc. | Results Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates biomeafusion.com ↗
The study demonstrated a clear, dose-dependent reduction in daily food intake and pronounced and continuous weight loss over a 28-day treatment period. |
| 2024-10-30 | Biomea Fusion Inc. | Results Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate biomeafusion.com ↗
BMF-650, an investigational next-generation, oral small-molecule GLP-1 receptor agonist (GLP-1 RA), demonstrated positive early preclinical activity, including improved glucose-stimulated insulin secretion, reduction in blood glucose concentration, and appetite suppression in cynomolgus monkeys |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMF-650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07223216 ↗ |
| Action | Activate | “GLP-1 receptor agonist” NCT07223216 ↗ |
| Modality | Small molecule | “an oral non-peptide GLP-1 receptor agonist” NCT07223216 ↗ |
| Route | Oral | “an oral non-peptide GLP-1 receptor agonist administered” NCT07223216 ↗ |